In the tumor microarray data, 1,693 probe-sets (1,115 upregulated and 578 downregulated) on the HG U133A platform were either significantly upregulated or downregulated in the PAX3(+/−Q)-FOXO1-positive ARMS tumors (n=16) compared to the fusion-negative ERMS tumors (n=15). This evidence concerns the gene PAX3 and alveolar rhabdomyosarcoma.